Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Lilly's new series of muscarinic cholinergic receptor agonists

May 24, 1996

Biogen introduces Avonex in first market

May 24, 1996

ICN will market fluoxetine in Russia, ex-Yugoslavia

May 24, 1996

Fujisawa, Nihon Shokubai claim CCK-B antagonists

May 24, 1996

ADIR claims melatonin receptor ligands for CNS disorders

May 24, 1996

Ultiva okayed for marketing in Germany; U.S. approval recommended by committee

May 24, 1996

Rizatriptan NDA filing expected in mid-1997

May 24, 1996

L-742694: Morpholine-based NK1 antagonist

May 24, 1996

CP-122721 shows potent affinity for NK1 receptors after oral dosing

May 24, 1996

Myotrophin up for advisory committee review

May 17, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.